Rapidly progressive Guillain-Barré syndrome following Escherichia coli infection

Internal Medicine

Volumn 46, Issue 9, 2007, Pages 589-591

  Kono, Yuriko ^a   Nishitarumizu, Kazutaka ^a   Higashi, Takuya ^b   Funakoshi, Kei ^c   Odaka, Masaaki ^c  

^a TEINE KEIJINKAI HOSPITAL   (Japan)

^b Nishimaruyama Hospital   (Japan)

^c DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Escherichia coli; Ga1NAc GD1a; GM1; Guillain Barr syndrome; Immunoabsorption

Indexed keywords

CATECHOLAMINE; CEPHALOSPORIN; GANGLIOSIDE GD 1A; GANGLIOSIDE GM1; GENTAMICIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; AUTOANTIBODY; GANGLIOSIDE; IMMUNOGLOBULIN G; IV(4) GALACTOSYL N ACETYLGANGLIOSIDE GD1A; IV(4)-GALACTOSYL-N-ACETYLGANGLIOSIDE GD1A; UNCLASSIFIED DRUG;

AGED; ANTIBODY TITER; ARTICLE; BACTERIAL INFECTION; CASE REPORT; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FEMALE; GUILLAIN BARRE SYNDROME; HUMAN; HYPOREFLEXIA; HYPOTENSION; IMMUNOADSORPTION; KIDNEY ABSCESS; MOTOR NEUROPATHY; MUSCLE WEAKNESS; NERVE CONDUCTION; PROTEIN CEREBROSPINAL FLUID LEVEL; URINALYSIS; ABSCESS; BLOOD; DISEASE COURSE; ENTEROBACTER INFECTION; IMMUNOLOGY; IMMUNOTHERAPY; KIDNEY DISEASE; METHODOLOGY; MICROBIOLOGY; PARAPLEGIA; PATHOLOGICAL REFLEX; PATHOPHYSIOLOGY; TIME;

ABSCESS; AGED; AUTOANTIBODIES; DISEASE PROGRESSION; ESCHERICHIA COLI INFECTIONS; FEMALE; G(M1) GANGLIOSIDE; GANGLIOSIDES; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNOGLOBULIN G; IMMUNOSORBENT TECHNIQUES; IMMUNOTHERAPY; KIDNEY DISEASES; NEURAL CONDUCTION; PARAPLEGIA; REFLEX, ABNORMAL; TIME FACTORS;

EID: 34249660480     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.46.6330     Document Type: Article

References (11)

1. Willison FU, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain 125: 2591-2625, 2002.
2. Yuki N, Tagawa Y, Irie F, Hirabayashi Y, Handa S. Close association of Guillain-Barré syndrome with antibodies to minor monosialogangliosides GM1b and GM1α. J Neuroimmunol 74: 30-34, 1997.
3. Bolton CF, Young GB. Neurological complications in critically ill patients. In: Neurology and General Medicine. 3rd ed. Churchill, Livingstone, 2001: 868-871.
4. Ropper AH. The Guillain-Barré syndrome. N EngI J Med 326 (17): 1130-1136, 1992.
5. Jacobs BC, Rothbarth PH, van der, Merche FG, et al. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology 51: 1110-1115, 1998.
6. Yuki N. Infectious origins of, and molecular mimicry in, Guillain-Barré and Fisher syndromes. Lancet Infect Dis 1: 29-37, 2001.
7. Funakoshi K, Koga M, Takahashi M, Hirata K, Yuki N. Campylobacter coli enteritis and Guillain-Barré syndrome: No evidence of molecular mimicry and serological relationship. J Neuro Sci 246: 163-168, 2006.
8. Kusunoki S, Chiba A, Kon K, et al. N-Acetylgalactosaminyl GD1 a is a target molecule for serum antibody in Guillain-Barré syndrome. Ann Neurol 35: 570-576, 1994.
9. Kaida K, Kusunoki S, Kamakura K, et al. Ga1NAc-GD1a in human peripheral nerve. Neurology 61: 465-470, 2003.
10. Yoshino H, Utsunomiya I, Taguchi K, et al. Ga1NAc-GD1a is localized specifically in ventral spinal roots, but not in dorsal spinal roots. Brain Res 1057: 177-180, 2005.
11. Willison HJ, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain 125: 2591-2625, 2002.